Other Proteins

TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T_H2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells.  It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4⁺T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was

TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T_H2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells.  It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4⁺T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was

TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T_H2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells.  It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4⁺T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was

TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T_H2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells.  It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4⁺T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was

TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, T_H2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells.  It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4⁺T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was

OX40 (also known as CD134, TNF receptor superfamily member 4, or TNFRSF4) is an immune checkpoint and a co-stimulatory receptor of the TNF (tumor necrosis factor) receptor family, expressed on the surface of T cells. Binding of OX40 to its ligand, OX40L (also known as CD252), potentiates T cell activation, differentiation, proliferation, survival, and T cell effector function. OX40L is present in NK cells, participating in their activation and cytotoxicity profile, and dendritic cells. OX40 can bind to members of the TRAF (TNFR associated factor) family of proteins, which can then regulate the NF-κF (nuclear factor kappa-light chain enhancer of activated B cells) signaling pathway. OX40 and OX40L can be found in cancer cells, such as AML (acute myeloid leukemia) and breast cancer cells. Studies have shown that OX40 agonists can increase anti-tumor immunity and improve tumor-free survival in pre-clinical studies. Alternatively, OX40 antagonists offer potential as therapeutics for inflam

CD155 (also known as PVR cell adhesion molecule) is a transmembrane glycoprotein receptor of the immunoglobulin superfamily of proteins. It is highly expressed in dendritic cells, fibroblasts, endothelial cells, and multiple tumor cells including ovarian carcinoma, non-small cell lung, glioblastoma, and colorectal carcinoma. It has a high affinity for a T cell regulatory transmembrane surface protein called TIGIT (T cell immunoglobulin and ITIM domains) and plays a key role in tumor cell invasion and migration. Interaction between CD155 and TIGIT causes immunosuppressive effects on CD4⁺ and CD8⁺ T cells, which hinders T cell proliferation and function. CD155 also interacts with the regulatory receptors CD226 (expressed on natural killer (NK) cells, monocytes and CD4⁺ T cells) and CD96. While CD155-CD226 engagement activates NK cell cytotoxicity and T cell response, CD155-CD96 interaction inhibits NK cell function. Due to these opposing regulatory effect

CD155 (also known as PVR cell adhesion molecule) is a transmembrane glycoprotein receptor of the immunoglobulin superfamily of proteins. It is highly expressed in dendritic cells, fibroblasts, endothelial cells, and multiple tumor cells including ovarian carcinoma, non-small cell lung, glioblastoma, and colorectal carcinoma. It has a high affinity for a T cell regulatory transmembrane surface protein called TIGIT (T cell immunoglobulin and ITIM domains) and plays a key role in tumor cell invasion and migration. Interaction between CD155 and TIGIT causes immunosuppressive effects on CD4⁺ and CD8⁺ T cells, which hinders T cell proliferation and function. CD155 also interacts with the regulatory receptors CD226 (expressed on natural killer (NK) cells, monocytes and CD4⁺ T cells) and CD96. While CD155-CD226 engagement activates NK cell cytotoxicity and T cell response, CD155-CD96 interaction inhibits NK cell function. Due to these opposing regulatory effect